Hachmo et al. 2020 showed HBOT lengthened telomeres and reduced senescent cell burden in aging adults — the first human telomere-elongation trial.
Quality: Very Low Insufficient recommendation
Hachmo 2020 (telomere length) is mechanistically interesting but clinical significance unclear. No hard-endpoint evidence.
The 2020 Hachmo et al. trial from the Efrati lab is the first human study to demonstrate telomere elongation and senescent cell reduction via a therapeutic intervention. 35 adults aged 64+ underwent 60 HBOT sessions at 2.0 ATA; peripheral blood immune cells showed significant telomere lengthening and reduction in senescent T cells. The findings have generated significant interest in HBOT as a longevity intervention, though replication is pending.
The Hachmo trial documented telomere elongation in peripheral blood immune cells and reduction in senescent T cells. Hypothesised mechanisms include HBOT-induced effects on telomerase activity, oxidative stress signalling, and anti-inflammatory effects on the senescence-associated secretory phenotype (SASP). The clinical significance of these cellular changes is unclear.
| Typical protocol | 60 sessions at 2.0 ATA |
|---|---|
| Evidence level | Early single-arm trial — Novel finding, replication pending |
| FDA / regulatory status | Not FDA-approved |
Hachmo protocol: 60 sessions at 2.0 ATA over 90 days (5 days per week), 90-minute sessions with air breaks.